Inhibition of the expression of α-smooth muscle actin in human hepatic stellate cell line, LI90, by a selective cyclooxygenase 2 inhibitor, NS-398

Biochemical and Biophysical Research Communications

Volumn 297, Issue 5, 2002, Pages 1128-1134

  Cheng, Jidong ^a,b   Imanishi, Hiroyasu ^a   Liu, Weidong ^a   Iwasaki, Atara ^a   Ueki, Noboru ^a   Nakamura, Hideji ^a   Hada, Toshikazu ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; COLLAGEN TYPE 4; CYCLINE; CYCLOOXYGENASE 2; HYALURONIC ACID; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2;

ARTICLE; CELL GROWTH; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; LIVER FIBROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STELLATE CELL;

ACTINS; BLOTTING, WESTERN; CELL LINE; COLLAGEN TYPE IV; CULTURE MEDIA; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EXTRACELLULAR MATRIX; HUMANS; HYALURONIC ACID; INTERLEUKIN-6; INTERLEUKIN-8; ISOENZYMES; LIVER; MEMBRANE PROTEINS; MUSCLE, SMOOTH; NITROBENZENES; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; TIME FACTORS;

EID: 0036402137     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(02)02301-X     Document Type: Article

References (39)

1. A. Ristimaki, S. Garfinkel, J. Wessendorf, T. Maciag, T. Hla, Induction of cyclooxygenase-2 by interleukin-1α; evidence for post-transcriptional regulation, J. Biol. Chem. 269 (1994) 11769-11775.
2. T. Hla, K. Neilson, Human cyclooxygenase-2 cDNA, Proc. Natl. Acad. Sci. USA 89 (1992) 7384-7388.
3. H. Koga, S. Sakisaka, M. Ohishi, J. Kawaguchi, E. Taniguchi, K. Sasatomi, M. Harada, T. Kusaba, M. Tanaka, R. Kimura, Y. Nakashima, O. Nakashima, M. Kojiro, T. Kurohiji, M. Sata, Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor differentiation, Hepatology 29 (1999) 688-696.
4. M. Kondo, H. Yamamoto, H. Nagano, J. Okami, Y. Ito, J. Shimizu, H. Eguchi, A. Miyamoto, K. Dono, K. Umeshita, N. Matsuura, K. Wakasa, S. Nakamori, M. Sakon, M. Monden, Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease free survival in patients with hepatocellular carcinoma, Clin. Cancer Res. 5 (1999) 4005-4012.
5. X.H. Liu, S. Yao, A. Kirschenbaum, A.C. Levine, NS-398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells, Cancer Res. 58 (1998) 4245-4249.
6. D.J. Elder, D.E. Halton, T.E. Crew, C. Paraskeva, Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398, Int. J. Cancer 86 (2000) 553-560.
7. M.A. Rahman, D.K. Dhar, R. Masunaga, A. Yamanoi, H. Kohno, N. Nagasue, Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines, Cancer Res. 60 (2000) 2085-2089.
8. J. Cheng, H. Imanishi, Y. Amuro, T. Hada, NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines, Int. J. Cancer 99 (2002) 755-761.
9. A. Denda, W. Kitayama, A. Murata, H. Kishida, Y. Sasaki, O. Kusuoka, T. Tsujiuchi, M. Tsutsumi, D. Nakae, H. Takagi, Y. Konishi, Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide, Carcinogenesis 23 (2002) 245-256.
10. δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2), Cell 87 (1996) 803-809.
11. M.G. Bachem, D. Meyer, R. Melchior, M. Sell, A.M. Gressner, Activation of rat liver perisinusoidal lipocytes by transforming growth factors derived from myofibroblast-like cell: a potential mechanism of self perpetuation in liver fibrogenesis, J. Clin. Invest. 89 (1992) 19-27.
12. A. Schmitt-Graff, S. Kruger, F. Bochard, G. Gabbiani, H. Denk, Modulation of a smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers, Am. J. Pathol. 138 (1991) 1233-1242.
13. C. Gallois, A. Habib, J. Tao, S. Moulin, J. Maclouf, A. Mallat, S. Lotersztajn, Role of NF-κB in the antiproliferative effect of endothelin-1 and tumor necrosis factor-α in human hepatic stellate cells involvement of cyclooxygenase-2, J. Biol. Chem. 273 (1998) 23183-23190.
14. K. Murakami, T. Abe, M. Miyazawa, M. Yamaguchi, T. Masuda, T. Matsuura, S. Nagamori, K. Takeuchi, K. Abe, M. Kyogoku, Establishment of a new human cell line, LI90, exhibiting characteristics of hepatic Ito (fat-storing) cells, Lab. Invest. 72 (1995) 731-739.
15. N. Ueki, T. Ohkawa, H. Yamamura, K. Takahashi, T. Tsutsui, Y. Kawai, Y. Yokoyama, Y. Amuro, T. Hada, K. Higashino, Induction of calponin-h1 by transforming growth factor-β1 in cultured human Ito cells, LI90, Biochim. Biophys. Acta 1403 (1998) 28-36.
16. S. Faouzi, S. Lepreux, C. Bedin, L. Dubuisson, C. Balabaud, P. Bioulac-Sage, A. Desmouliere, J.. Rosenbaum, Activation of cultured rat hepatic stellate cells by tumoral hepatocytes, Lab. Invest. 79 (1999) 485-493.
17. S. Blazejewski, A.M. Preaux, A. Mallat, I. Brocherion, P. Mavier, D. Dhumeaux, D. Hartmann, D. Schuppan, J. Rosenbaum, Human myofibroblast-like cells obtained by outgrowth are representative of the fibrogenic cells in the liver, Hepatology 22 (1995) 788-797.
18. I. Ozaki, G. Zhao, T. Mizuta, Y. Ogawa, T. Hara, S. Kajihara, A. Hisatomi, T. Sakai, K. Yamamoto, Hepatocyte growth factor induces collagenase (matrix metalloproteinase-1) via the transcription factor Ets-1 in human hepatic stellate cell line, J. Hepatol. 36 (2002) 169-178.
19. N. Ueki, T. Taguchi, M. Takahashi, M. Adachi, T. Ohkawa, Y. Amuro, T. Hada, K. Higashino, Inhibition of hyaluronan synthesis by vesnarinone in cultured human myofibroblasts, Biochim. Biophys. Acta 1495 (2000) 160-167.
20. S. Imai, M. Okuno, H. Moriwaki, Y. Muto, K. Murakami, K. Shudo, Y. Suzuki, S. Kojima, 9,13-di-cis-Retinoic acid induces the production of tPA and activation of latent TGF-β via RAR α in a human liver stellate cell line, LI90, FEBS Lett. 411 (1997) 102-106.
21. G.A. Kune, S. Kune, L.F. Watson, Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study, Cancer Res. 48 (1988) 4399-4404.
22. S.M. Prescott, F.A. Fitzpatrick, Cyclooxygenase-2 and carcinogenesis, Biochim. Biophys. Acta 1470 (1988) M69-M78.
23. S.H. Bae, E.S. Jung, Y.M. Park, B.S. Kim, B.K. Kim, D.G. Kim, W.S. Ryu, Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398, Clin. Cancer Res. 7 (2001) 1410-1418.
24. 2 in the liver tissue of patients with chronic hepatitis and liver cirrhosis, Hepatol. Res. 23 (2002) 185-195.
25. Z. Kelman, PCNA: structure, functions and interactions, Oncogene 14 (1997) 629-640.
26. C.A. Torres-Ramos, B.L. Yoder, P.M. Burgers, S. Prakash, L. Prakash, Requirement of proliferating cell nuclear antigen in RAD6-dependent postreplicational DNA repair, Proc. Natl. Acad. Sci. USA 93 (1996) 9676-9681.
27. A. Umar, A.B. Buermeyer, J.A. Simon, D.C. Thomas, A.B. Clark, R.M. Liskay, T.A. Kunkel, Requirement for PCNA in DNA mismatch repair at a step preceding DNA resynthesis, Cell 87 (1996) 65-73.
28. C. Herrmann, C. Block, C. Geisen, K. Haas, C. Weber, G. Winde, T. Moroy, O. Muller, Sulindac sulfide inhibits Ras signaling, Oncogene 17 (1998) 1769-1776.
29. W.R. Waddell, R.L. Miesfeld, Adenomatous polyposis coli, protein kinases protein tyrosine phosphatase: the effect of sulindac, J. Surg. Oncol. 58 (1995) 252-256.
30. Y. Yamamoto, M.J. Yin, K.M. Lin, R.B. Gaynor, Sulindac inhibits activation of the NF-κB pathway, J. Biol. Chem. 274 (1999) 27307-27314.
31. T.A. Chan, P.J. Morin, B. Vogelstein, K.W. Kinzler, Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis, Proc. Natl. Acad. Sci. USA 95 (1998) 681-686.
32. G.A. Piazza, A.K. Rahm, T.S. Finn, B.H. Fryer, H. Li, A.L. Stoumen, R. Pamukcu, D.J. Ahnen, Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition. Cell cycle arrest, and p53 induction, Cancer Res. 57 (1997) 2452-2459.
33. S.J. Shiff, L. Liao, L.L. Tsai, B. Rigas, Sulindac Sulfide, an Aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colin adenocarcinoma cells, J. Clin. Invest. 96 (1995) 491-503.
34. D.J. Elder, D.E. Halton, A. Hague, C. Paraskeva, Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression, Clin. Cancer Res. 3 (1997) 1679-1683.
35. P. Bedossa, E. Peltier, B. Terris, D. Franco, T. Poynard, Transforming growth factor-β-1 (TGF-β1) and TGF-β1 receptors in normal, cirrhotic, and neoplastic human livers, Hepatology 21 (1995) 760-766.
36. J. Napoli, G.A. Bishop, G.W. Mccaughan, Increased intrahepatic messenger RNA expression of interleukins 2, 6, and 8 in human cirrhosis, Gastroenterology 107 (1994) 789-798.
37. S.C. Afford, N.C. Fisher, D.A. Neil, J. Fear, P. Brun, S.G. Hubscher, D.H. Adams, Distinct patterns of chemokine expression are associated with leukocyte recruitment in alcoholic hepatitis and alcoholic cirrhosis, J. Pathol. 186 (1998) 82-89.
38. V. Vasiliou, J. Lee, A. Pappa, D.R. Petersen, Involvement of p65 in the regulation of NF-κB in rat hepatic stellate cells during cirrhosis, Biochem. Biophys. Res. Commun. 273 (2000) 546-550.
39. M. Mohamadzadeh, H. DeGrendele, H. Arizpe, P. Estess, M. Siegelman, Proinflammatory stimuli regulate endothelial hyaluronan expression and CD44/HA-dependent primary adhesion, J. Clin. Invest. 101 (1998) 97-108.